[Pharmacological properties and clinical efficacy of fingolimod hydrochloride (Imusera®/Gilenya®) for the treatment of multiple sclerosis]

Nihon Yakurigaku Zasshi. 2012 Jun;139(6):265-74. doi: 10.1254/fpj.139.265.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Animals
  • Clinical Trials, Phase I as Topic
  • Disease Models, Animal
  • Encephalomyelitis, Autoimmune, Experimental / drug therapy
  • Encephalomyelitis, Autoimmune, Experimental / prevention & control
  • Fingolimod Hydrochloride
  • Humans
  • Lymphocytes / physiology
  • Lysophospholipids / physiology
  • Multiple Sclerosis / drug therapy*
  • Propylene Glycols / administration & dosage*
  • Propylene Glycols / pharmacology*
  • Receptors, Lysosphingolipid / antagonists & inhibitors
  • Secondary Prevention
  • Sphingosine / administration & dosage
  • Sphingosine / analogs & derivatives*
  • Sphingosine / pharmacology
  • Sphingosine / physiology
  • Th17 Cells / immunology

Substances

  • Lysophospholipids
  • Propylene Glycols
  • Receptors, Lysosphingolipid
  • sphingosine 1-phosphate
  • Fingolimod Hydrochloride
  • Sphingosine